Leafcann Group

Leafcann Group is an Australian medicinal cannabis company dedicated to the research, cultivation, and manufacture of pharmaceutical-grade cannabinoid medicines. Established in 2016, the company focuses on delivering high-quality, evidence-based treatments for patients suffering from chronic and debilitating conditions. Leafcann operates a vertically integrated model, encompassing everything from genetic selection and cultivation to extraction and final product formulation. The company holds essential licenses from the Australian Office of Drug Control, including those for medicinal cannabis cultivation, production, and manufacture. Their primary goal is to bridge the gap between traditional medicine and cannabinoid therapy through rigorous clinical research and GMP-compliant production standards. Leafcann's product portfolio is designed to address therapeutic areas such as chronic pain, epilepsy, and palliative care.